Alzheimer's disease (AD) causes gradual cognitive decline and dementia.
Until recently, the definitive diagnosis of AD was based on autopsy assessments of brain amyloid-β plaques and tau neurofibrillary tangles, the defining biological features of AD. Biomarkers of amyloid-β and tau are vital for measuring AD pathology in living people and for differentiating between different neurodegenerative diseases.
With the latest progress in AD research, accurate in-vivo diagnosis of AD is becoming increasingly crucial: before starting treatment with anti-amyloid therapies, it's essential to determine if amyloid positivity is present. This article...
Join this channel to get access to perks:
When dealing with any medically related events or medical emergencies, please communicate with your primary health care...
🔓 Unlock access to MedCircle’s workshops & series, plus connect with others who have been impacted by dementia through your MedCircle Community.
Join now:
How's...
Recent studies have shown new antibody drugs to slow cognitive decline among people with early-onset Alzheimer's – a critical finding, given that the disease...
Looking for an evaluation? Click here: brainhealthneuro.com
What are some early signs of dementia, and when should you be concerned?
#neuropsychology #dementia #alzheimers
Neuropsychologist | Diagnosis |...